Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease

Gynecological Endocrinology

Volumn 19, Issue 4, 2004, Pages 196-201

  Karabacak, I Y N I ^a   Karabacak, O ^a   Toruner F B ^a   Akdemir, O ^a   Arslan, M ^a   Yetkin, I ^b  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Fluoxetine; Leptin; Obesity; Polycystic ovary syndrome; Sibutramine

Indexed keywords

FLUOXETINE; LEPTIN; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

ADULT; ARTICLE; BASAL METABOLIC RATE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THERMOGENESIS; WEIGHT REDUCTION;

ADULT; APPETITE DEPRESSANTS; BODY MASS INDEX; CYCLOBUTANES; FEMALE; FLUOXETINE; FOLLICLE STIMULATING HORMONE; GLUCOSE TOLERANCE TEST; HUMANS; LEPTIN; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 12244268003     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590400012077     Document Type: Article

References (26)

1. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992;36:105-11
2. Hamilton-Fairley D, Kiddy D, Anyaoku V, et al. Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clin Endocrinol 1993;39:363-7
3. Bates GW, Whitworth NS. Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril 1982;38:406-9
4. Harlass FE, Plymate SR, Fariss BL, et al. Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female. Fertil Steril 1984;42:649-52
5. Jakubowicz DJ, Nestler JE. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 1997;82:556-60
6. Bützow T, Lehtovirta M, Siegberg R, et al. The decrease in luteinizing hormone secretion in response to weight reduction is inversely related to the severity of insulin resistance in overweight women. J Clin Endocrinol Metab 2000;85:3271-5
7. Porte D Jr, Seeley RJ, Woods SC, et al. Obesity, diabetes and the central nervous system. Diabetologia 1998;41:863-81
8. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000;404:661-71
9. Adams J, Franks S, Polson DW, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985;2:1375-9
10. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002;25 (Suppl 1):S5-20
11. Dunaif A, Segal KR., Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-73
12. Luscombe GP, Hopcroft RH, Thomas PC, et al. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989;28:129-34
13. Heal DJ, Cheetham SC, Prow MR., et al. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol 1998;125:301-8
14. Jackson H C, Bearham MC, Hutchins LJ, et al. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997;121:1613-18
15. Jackson HC, Needham AM, Hutchins LJ, et al. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 1997;121:1758-62
16. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti obesity agent. Int J Obes 1997;21 (Suppl 1):S25-9
17. Heal DJ, Aspley S, Prow MR, et al. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998;22 (Suppl 1):S18-28
18. Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:575-84
19. Martin KF, Phillips I, Hearson M, et al. Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants. Br J Pharmacol 1992;107:15-21
20. Hansen DL, Toubro S, Stock MJ, et al. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68:1180-6
21. Hansen DL, Toubro S, Stock MJ, et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes 1999;23:1016-24
22. Stricker-Kongrad A, Souquet AM, Burlet C. Effects of sibutramine on feeding behaviour in dietary-induced obesity: role of dietary constituents. Int J Obes 1995;19 (Suppl 2):145
23. Rolls BJ, Shide DJ, Thorwart ML, et al. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998;6:1-11
24. Connoley IP, Liu YL, Frost I, et al. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 1999;126:1487-95
25. Liu YL, Heal DJ, Stock MJ. Mechanism of the thermogenic effect of metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine. Int J Obes Relat Metab Disord 2002;26:1245-53
26. Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res 1998;6:115-21